Drugmakers in Davos shift focus to chronic diseases of poor
50 million USD for the treatment of non-communicable diseases in developing and emerging countries
Reuters 22 global pharmaceutical companies have decided to invest 50 million USD for the next three years to reduce the number of deaths caused by non-communicable diseases (NCDs) by one-third until 2030. This will also be an important measure with regard to the United Nations sustainable development goals.
The first focus of the newly established so-called Access Accelerated Initiative, which is supported by the World Bank and the Union for International Cancer Control (UICC), aims to test out new diagnostics and treatments. (Photo: biologycorner/flickr)